[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-adult":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,52,83,108,139,167,195,219,250,298,334,362,389,415,461,481,503,530],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633664","association-between-chronic-psychological-stress-and-disease-course-outcomes-in-pancreatic-cancer-100633664",false,"NCT07529626","Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer","A Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)","MIND-PANC","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer, or other pancreatic diseases.\n* Conscious, with basic reading\u002Fwriting or communication skills, able to understand and complete the questionnaire assessments (either independently, with assistance from research staff, or with help from a family member).\n* Voluntarily agree to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe cognitive impairment (e.g., dementia, disturbance of consciousness) or a definite history of psychiatric disorders, judged by the investigator as unable to comply with the study assessments, and without a family member who can help complete the questionnaire assessments.\n* Presence of other severe, uncontrolled systemic diseases (e.g., severe heart, lung, or kidney failure), with an estimated life expectancy \\\u003C 3 months as judged by the investigator.\n* Inability to understand Chinese or presence of severe visual\u002Fhearing impairment that affects completion of the questionnaire assessments, and without a family member who can help complete the questionnaire assessments.","ALL","18 Years",{"count":20,"type":21},320,"ESTIMATED","3 Years","OBSERVATIONAL","This is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer.\n\nResearchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers.\n\nInvestigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.",[26,27,28],"Pancreatic Tumor, Benign","Pancreatic Cancer, Adult","Pancreatic Cancer Resectable",[30,31,32,33,34,35,36,37,38],"pancreatic cancer","anxiety","depression","psychological distress","Hospital Anxiety and Depression Scale","Pittsburgh Sleep Quality Index","disease progression","Overall survival","quality of life","RECRUITING","2026-06-24",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2026-05-11",{"date":47,"type":21},"2028-12-31",{"name":49,"class":50},"Shanghai Zhongshan Hospital","OTHER",3,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100637413","phase-2-befast-study-68gaga-fapi-total-body-petct-for-better-and-faster-imaging-in-cancer-100637413","NCT07629609","BEFAST Study, [68Ga]Ga-FAPI Total Body PET\u002FCT for Better and Faster Imaging in Cancer","[68Ga]Ga-FAPI Total Body PET\u002FCT for Improving Diagnostic Sensitivity and Preoperative Staging in Gastroesophageal Cancer and Pancreatic Cancer","BEFAST","Inclusion criteria for group A\n\n1. Male or female, over 18 years old\n2. Patients with suspected pancreatic cancer based on morphological findings on standard imaging\n3. CT or MRI or \\[18F\\]FDG PET\u002FCT evaluated on MDT with no initial sign of distant metastases\n4. Subjects must have been considered suitable for curative surgery at the time of the referral\n5. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nInclusion criteria for group B1\n\n1. Male or female over 18 years old\n2. Histological verified carcinoma from the lower esophagus, GEJ, or stomach\n3. Subjects must be considered operable and resectable at the time of referral for MDT\n4. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nInclusion criteria for group B2\n\n1. Male or female over 18 years old\n2. Histological verified SRCC or PCC from the lower esophagus, GEJ, or stomach\n3. Subjects with localized disease assigned to perioperative chemotherapy or subjects with metastatic disease assigned to palliative systemic treatment.\n4. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Weight more than the maximum limit of a PET\u002FCT-scanner bed (140 kg)\n3. History of allergic reaction due to compounds similar to the chemical composition of \\[68Ga\\]Ga-FAPI-46",{"count":61,"type":21},90,"INTERVENTIONAL",[64],"PHASE2","The goal of this clinical trial is to learn if \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT can diagnose patients suffering from gastroesophageal cancer and pancreatic cancer. The investigators hope that \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT can improve staging and treatment evaluation for these patient groups.\n\nThe main questions the trial aims to answer are:\n\n* Is \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT better at diagnosing metastatic disease in the abdomen compared other imaging modalities?\n* Can \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT produce accurate images in less than 30 min?\n\nResearchers will examine three different patient groups:\n\nGroup A) patients with pancreatic cancer, who are referred to surgery. Group B1) patients with gastroesophageal cancer, who are referred to diagnostic surgery (laparoscopy).\n\nGroup B2) a subgroup of gastroesophageal cancer patients, with a specific subtype cancer (signet ring cell carcinoma or poorly cohesive carcinoma), who are referred to oncological treatment.\n\nParticipants will undergo:\n\n* One \\[68Ga\\]Ga-FAPI Total Body PET\u002FCT before surgery (Group A), or before laparoscopy (group B1), or before oncological treatment (Group B2).\n* Participants in group B2 will also undergo a second \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT during treatment with chemotherapy.\n* All participants will fill out one questionnaire.\n* Researchers will follow the patients after the scans for 1 year.",[27,67],"Gastroesophageal Cancer (GC)",[69,70,30,71,72],"PET\u002FCT","FAPI","gastroesophageal cancer","signet ring cell carcinoma","2026-06-01",{"date":75,"type":43},"2026-06-05",{"date":77,"type":43},"2024-01-16",{"date":79,"type":21},"2027-01",{"name":81,"class":50},"Barbara Malene Fischer",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":62,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":82},"100639860","to-evaluate-the-preliminary-efficacy-of-our-digitally-enhanced-chw-led-intervention-in-newly-diagnosed-pdac-100639860","NCT07591571","To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC","To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC With a Pilot Randomized Controlled Trial of 60 PDAC Patients and Their Caregivers Comparing the Intervention to Attention Control With Usual Care.","Inclusion criteria:\n\n* Age 18 to 90\n* English or Spanish-Speaking\n* Diagnosed with Newly-Diagnosed Pancreatic Adenocarcinoma or has a pancreatic mass on CT\u002FMRI with suspected PDAC and is awaiting biopsy.\n* Able to communicate verbally to allow for audio recording to complete an exit interview\n* Must be able to consent\n\nExclusion criteria:\n\n• Biopsy Does not Confirm Adenocarcinoma of the Pancreas","18 Months",{"count":92,"type":21},60,[94],"NA","The goal of this clinical trial is to learn if a community health worker led intervention that helps facilitate palliative care works to treat newly-diagnostic pancreatic cancer. It will also help understand the impact of this intervention on people who are caregivers for patients with pancreatic cancer. The main questions it aims to answer are:\n\nDoes the community health worker improve symptoms and quality of life in patients with pancreatic cancer? Does the community health worker improve the burden of caregiving and quality of life in family caregivers? Researchers will compare drug ABC to a control (where patients get the care that patients with pancreatic cancer receive including access to handouts and videos that the investigators provide patients by national organizations) to see if the intervention works to help patients with pancreatic cancer.\n\nParticipants will:\n\nMeet with study staff several times over 3 months and complete surveys about their experience and symptoms Patients assigned with the community health worker will meet with them in person or video.",[27],[98,30,99],"community health worker","palliative care",{"date":101,"type":43},"2026-05-15",{"date":103,"type":43},"2025-09-01",{"date":105,"type":21},"2026-09-01",{"name":107,"class":50},"Loma Linda University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":82},"100439733","pancreatic-cancer-screening-for-at-risk-individuals-100439733","NCT05006131","Pancreatic Cancer Screening for At-risk Individuals","Pancreatic Cancer Screening for At-risk Individuals (The Pancreas Scan Study)","PancreasScan","Inclusion Criteria:\n\n* Inclusion criteria 1-3 are indications for pancreatic cancer screening as defined by the CAPS3 guidelines or updated national pancreatic cancer screening guidelines. Patients who do not meet these guidelines but are undergoing pancreatic cancer screening at the discretion of their treating physician at participating study centers will also be included in the study. Based upon the indication for screening, patients will be categorized as either meeting CAPS3 screening criteria, or not meeting CAPS3 screening criteria.\n\n  1. Familial Pancreatic cancer kindred. This is defined as family history of pancreas cancer that meet the criteria listed below.\n\n     1. If at least two affected relatives who are First degree relatives (FDR) to each other, of whom at least one is an FDR to the individual considered for surveillance\n     2. If at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance\n     3. If at least two affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance Screening is usually initialed at age 50 years or 10 years younger than the youngest family member with pancreatic cancer\n  2. Patients with genetic susceptibility to pancreas cancer\n\n     1. Patients with Peutz-Jeghers syndrome diagnosed with using clinical criteria or with a deleterious mutation in liver kinase B1\u002FSerine\u002Fthreonine kinase 11 (LKB1\u002FSTK11). Screening is usually initiated at age 40 years or later.\n     2. Patients with Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM syndrome), diagnosed using clinical criteria or CDKN2A p16 mutation.\n\nScreening is usually initiated at age 45 years or 10 years younger than the youngest family member with pancreatic cancer.\n\n1. Hereditary Breast and Ovarian Cancer syndrome: diagnosed using clinical criteria or deleterious Breast Cancer gene 1 (BRCA1), Breast Cancer gene 2 (BRCA2), Partner and Localizer of BRCA2 (PALB2). The usual indication for screening is:\n\n   * BRCA1 mutation and at least one affected first-degree relative with pancreatic cancer\n   * BRCA 2 mutation and at least one affected first-degree relative, or at least two relatives of any degree with pancreatic cancer\n   * PALB2 mutation and at least one affected first-degree relative with pancreatic cancer Screening is usually initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer; or per updated national screening guidelines\n2. Lynch syndrome or Ataxia Telangiectasia Mutated (ATM) mutations with at least one affected first-degree relative (FDR). Lynch syndrome could be diagnosed either by using clinical criteria or Mutator L homolog 1 (MLH1), Mutator S homolog 2 (MSH2), Mutator S homolog 6 (MSH6), Postmeiotic Segregation Increased, S. Cerevisiae, 2 (PMS2) or EPCAM mutation.\n\n   Screening to be initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer.\n3. Patients with hereditary pancreatitis diagnosed using clinical criteria or deleterious Serine Protease 1 (PRSS1) mutation. Screening is usually initiated at age 40 years or 10 years younger than the youngest family member with pancreatic cancer 3. New-onset diabetes, age \\> 50 years with weight loss. 4. Patients who do not meet these CAPS screening criteria but are determined by the site principal investigator to be high-risk for pancreatic cancer based upon family history or other risk factors, and are undergoing pancreatic cancer screening will also be included in the study. Indication for pancreatic cancer screening and age at which screening was initiated will be recorded.\n\nExclusion Criteria:\n\n* Patients presenting with symptoms suggestive of pancreatic cancer who are undergoing diagnostic EUS or MRCP e.g. acute recurrent pancreatitis, abnormal imaging","90 Years",{"count":118,"type":21},1395,"The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes.",[27],[122,123,124,125,126,127,128,129],"Pancreatic cancer screening","Early detection of pancreatic cancer","Genetic susceptibility to pancreatic cancer","BRCA 1","BRCA 2","familial pancreatic cancer","Endoscopic Ultrasound","MRI","2026-04-21",{"date":132,"type":43},"2026-04-23",{"date":134,"type":43},"2020-07-10",{"date":136,"type":21},"2032-12-31",{"name":138,"class":50},"Beth Israel Deaconess Medical Center",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":62,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":82},"100629708","prehab-for-pancreatic-cancer-surgery-100629708","NCT07478185","Prehab for Pancreatic Cancer Surgery","Multimodal Prehabilitation Prior to Pancreatic Cancer Surgery: A Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of pancreatic ductal adenocarcinoma (PDAC)\n* Planned neoadjuvant chemotherapy prior to planned surgical resection\n* Medically stable and cleared to participate in physical activity\u002Fexercise programming\n* Able to provide informed consent\n* Ability to read, write and understand English\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnant\n* Prisoner\n* Severe cognitive impairment that precludes informed consent or participation\n* Contraindications to physical activity, including unstable cardiac disease, severe pulmonary disease, or recent myocardial infarction",{"count":147,"type":21},20,[94],"The goal of this clinical study is to test whether a structured prehabilitation program can be successfully used by adults with pancreatic cancer who are receiving chemotherapy before planned surgery. Prehabilitation is a program designed to improve a person's physical fitness, nutrition, and symptom control before surgery.\n\nThe study's main hypothesis is that patients with pancreatic cancer can take part in and adhere to a multimodal prehabilitation program during chemotherapy, and that doing so may improve physical function, patient experience, and early recovery after surgery.",[27,151],"Prehabilitation",[151,153,154,155,156,157],"Nutritional status","Functional capacity","Pancreatic cancer","Pancreatectomy","Pancreaticoduodenectomy","2026-04-01",{"date":160,"type":43},"2026-04-03",{"date":162,"type":43},"2026-03-31",{"date":164,"type":21},"2028-12",{"name":166,"class":50},"University of Massachusetts, Worcester",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":62,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100577859","surveillance-of-pancreatic-health-after-diabetes-diagnosis-100577859","NCT06803771","Surveillance of Pancreatic Health After Diabetes Diagnosis","A Randomised Trial to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Patients With Newly Diagnosed Diabetes Mellitus","SAFE-D","Inclusion Criteria:\n\n* 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)\n* Haemoglobin A1c (HbA1c) ≥ 48 or 6.5% and\u002For confirmed type II DM diagnosed within the last 180 days (+20 days flexibility allowance)\n* Willing to provide up to 30 mL of blood for each study visit\n* Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated)\n* Understands the study process and is willing to take part in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* Prior type I or type II DM diagnosis \\> 6 months\n* A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis\n* Under investigation for pancreatic cancer \u002F pancreatic cyst\n* Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months\n* Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years\n* Current chronic or acute oral or systemic steroid use within 3 months of initial HbA1c or diabetes diagnosis (estimate rather than accurate)\n* Blood transfusion within 1 month\n* Solid organ transplant recipient\n* Currently pregnant\n* Needing dialysis","50 Years","84 Years",{"count":178,"type":21},15000,[94],"The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months.\n\nParticipants will:\n\n* attend 3 study visits over 12 months time\n* provide a blood sample at each study visit\n* complete an anxiety questionnaire at each visit.",[182,27],"Diabetes Mellitus",[184,30],"Type 2 diabetes","2026-03-20",{"date":187,"type":43},"2026-03-23",{"date":189,"type":43},"2025-05-21",{"date":191,"type":21},"2029-02",{"name":193,"class":50},"University Hospital Southampton NHS Foundation Trust",31,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":62,"phases":205,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":82},"100626523","phase-3-surufatinib-plus-gemcitabine-and-nab-paclitaxel-vs-gemcitabine-plus-nab-paclitaxel-in-neoadjuvant-therapy-for-high---risk-resectable-or-borderline-resectable-pancreatic-cancer-100626523","NCT07436741","Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer","A Prospective, Randomized, Controlled, Multi-center Clinical Trial of Surufatinib Combined With Gemcitabine and Nab-paclitaxel Versus Gemcitabine Combined With Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;\n* 18-75 years old (including 18 and 75 years old);\n* No BRCA1\u002F2 or PALB2 mutation;\n* No previous pancreatic cancer resection, systemic therapy, or local radiation therapy;\n* Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;\n* Life expectancy ≥ 6 months;\n* At least one measurable lesion according to RECIST version 1.1;\n* Adequate organ and bone marrow functions;\n* Women of childbearing age need to take effective contraceptive measures.\n\nExclusion Criteria:\n\n* With distant metastasis;\n* Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;\n* Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);\n* Allergic to the study drug or any of its adjuvants;\n* Researchers judged clinically significant electrolyte abnormalities;\n* History of serious cardiovascular and cerebrovascular diseases;\n* With active ulcer, intestinal perforation and intestinal obstruction;\n* Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture according to the judgment of the investigator);\n* Clinically significant electrolyte abnormalities judged by researchers;\n* With active bleeding or obvious evidence of bleeding tendency;\n* Hypertension that cannot be controlled by drugs: systolic blood pressure ≥ 150 mmHg and \u002F or diastolic blood pressure ≥ 100 mmHg;\n* Women who are pregnant or lactating;\n* Urinary protein ≥ ++, or the 24-hour urine protein quantification is greater than 1.0g;\n* Concurrent tumors within 5 years (except treated cervical carcinoma in situ, basal cell carcinoma);\n* Any disease or state that affects the absorption of drugs, or the subject cannot take oral drugs;\n* Known human immunodeficiency virus (HIV) infection;\n* History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×10\\^4\u002Fml or \\>2000 IU\u002Fml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×10\\^3\u002Fm); hepatitis and cirrhosis;\n* Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.","75 Years",{"count":204,"type":21},106,[206],"PHASE3","To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer",[27],"NOT_YET_RECRUITING","2026-02-22",{"date":212,"type":43},"2026-02-27",{"date":214,"type":21},"2026-02",{"date":216,"type":21},"2030-03",{"name":218,"class":50},"Tianjin Medical University Cancer Institute and Hospital",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":62,"phases":229,"briefSummary":230,"conditions":231,"keywords":237,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":82},"100360753","phase-2-tumor-subtypes-in-subjects-on-folfirinox-with-non-metastatic-pancreatic-cancer-100360753","NCT03977233","Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease.\n* Subject has no evidence of co-morbidities precluding the potential to undergo surgical resection of PDAC as determined by surgical investigator.\n* Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guided core biopsy of the pancreatic mass.\n* Measurable or non-measurable but evaluable (as determined by Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\]) resectable, borderline resectable or unresectable locally advanced PDAC.\n* Subject has adequate performance status as defined by ECOG performance status 0 or 1.\n* Subject has received no prior chemotherapy or chemoradiotherapy for pancreatic cancer. Subjects have not previously received surgery to remove pancreatic cancer.\n* Age ≥ 18 years of age.\n* Subject has adequate organ function at study entry.\n* Subject has life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n* Subject has any evidence of local recurrence or metastatic pancreatic cancer.\n* Other malignancies within the past 5 years except for adequately treated cervical or vulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).\n* Subject has hypersensitivity to 5FU, oxaliplatin or other platinum agent, or irinotecan or to their excipients.\n* Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.\n* Participation in any investigational drug study within 4 weeks preceding the start of study treatment. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol. Subjects participating in other clinical trials that are receiving SOC FOLFIRINOX are permitted on study.\n* Subject has current evidence of any condition that makes participating in this study not in the best interest of the subject, including but not limited to:\n\n  * Myocardial infarction within the past 6 months\n  * New York Heart Association (NYHA) Class III or IV heart disease\n  * Active infection requiring IV antibiotics\n* Subject has a history of or suspected Gilbert's syndrome or known homozygosity for UGT1A1\\*28 polymorphism (baseline testing not required).\n* Subject has sensory peripheral neuropathy grade ≥ 2.\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.\n* Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated. If subjects require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study.\n* Subject is pregnant or lactating.\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.","99 Years",{"count":228,"type":21},45,[64],"This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.\n\nChemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery.\n\nResearchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell.\n\nDepending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.",[232,233,27,234,235,236,28],"Pancreatic Ductal Adenocarcinoma (PDAC)","Cancer of Pancreas","Pancreas Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Non-resectable",[238,236,28,239,240,27],"Pancreatic Ductal Adenocarcinoma","neoadjuvant FOLFIRNOX","FOLFIRINOX","2026-01-09",{"date":243,"type":43},"2026-01-13",{"date":245,"type":43},"2019-06-12",{"date":247,"type":21},"2030-01",{"name":249,"class":50},"UNC Lineberger Comprehensive Cancer Center",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":257,"sex":17,"minAge":258,"maxAge":202,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":270,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":297},"100571211","the-ccaned-cipher-study-early-cancer-detection-and-treatment-response-monitoring-using-ai-based-platelet-and-immune-cell-transcriptomic-profiling-100571211","NCT06717295","The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","CCANED-CIPHER","Phase 1 (Common Cancer Early Detection - CCANED)\n\nInclusion Criteria:\n\n* Age: Adults aged 40 years or older.\n* Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.\n\nExclusion Criteria:\n\n* Currently pregnant.\n* Presence of any active infectious diseases.\n* Use of anticoagulant or antiplatelet drugs within the past 2 weeks.\n* Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.\n\nPhase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)\n\nInclusion Criteria:\n\n* Adults aged 40 years or older.\n* Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)\n* Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).\n\nExclusion Criteria:\n\n* Presence of another malignancy unless it has been in remission for at least 5 years.\n* Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.",true,"40 Years",{"count":260,"type":21},6000,"The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.",[263,264,27,265,266,267,268,269],"Brest Cancer","Lung Cancer (NSCLC)","Prostate Cancers","Ovarian Cancer","Colorectal Cancer","Glioblastoma (GBM)","Liver Carcinoma",[271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286],"cancer screening","Liquid Biopsy","AI-based Diagnostics","Early Cancer Detection","Circulating Tumor DNA (ctDNA)","RNA Profiling","Biomarker","Precision Medicine","Oncology","Health Data Analysis","Platelets","treatment response","RNA","CircRNA","Splicing","Cancer","2025-12-29",{"date":289,"type":43},"2026-01-02",{"date":291,"type":43},"2025-12-20",{"date":293,"type":21},"2028-08-01",{"name":295,"class":296},"Javier Toledo","INDUSTRY",4,{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":257,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":308,"conditions":309,"keywords":318,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100545979","pancreatic-cancer-detection-consortium-100545979","NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",{"count":307,"type":21},2000,"This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[310,311,312,238,235,313,314,28,315,316,317,27,236],"Pancreatic Cancer","Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III",[319,320,321,322,323],"Micro RNA","Exosome","Cell free","Early detection","Screening","2025-12-17",{"date":326,"type":43},"2025-12-19",{"date":328,"type":43},"2023-03-15",{"date":330,"type":21},"2026-06-18",{"name":332,"class":50},"City of Hope Medical Center",11,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":342,"targetDuration":4,"studyType":62,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":82},"100560982","phase-2-adebrelimab-and-chidamide-for-pancreatic-cancer-100560982","NCT06584227","Adebrelimab and Chidamide for Pancreatic Cancer","A Single-Arm, Multicenter, Open, Phase II Clinical Study of Adebrelimab and Chidamide in Combination With Gemcitabine and S1 for the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer","ACPC","Inclusion Criteria:\n\n1. 18 to 75 years old;\n2. Histologically or cytologically confirmed pancreatic cancer (originating from the ductal epithelium of the pancreas) with clinically documented unresectable locally advanced or metastatic pancreatic cancer (stage III\u002FIV according to the TNM stage of AJCC 8 pancreatic cancer);\n3. have not previously received systematic antitumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeting, immunotherapy or investigational therapy;\n4. There must be at least one measurable lesion as a target lesion (according to RECIST v1.1 standards);\n5. ECOG(American Eastern Cancer Collaboration) Physical status score: 0\\~1;\n6. Expected survival ≥3 months;\n7. The function of major organs is good (no blood components, cell growth factors, whitening drugs, platelet drugs, anemia correction drugs are allowed within 14 days before enrollment);\n8. Women of childbearing age must have had a blood pregnancy test within 7 days prior to enrollment, with a negative result, and be willing to use an appropriate method of contraception during the trial period and for 6 months after the end of treatment. For men, they should be surgically sterilized or agree to use an appropriate method of contraception during the study period and for 3 months after the end of treatment;\n9. Voluntarily participate in the study and sign the informed consent;\n10. Good compliance, agreed to cooperate with the survival follow-up.\n\nExclusion Criteria:\n\n1\\) Have received any of the following treatments:\n\n1. Previous treatment with ICIs or HDACi;\n2. Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within 4 weeks before enrollment;\n3. Received any other investigational drug\u002Fdevice treatment within 4 weeks prior to enrollment;\n4. Enrolling in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up; 2) Patients known to be allergic to the components of the investigational drug; 3) Patients with known central nervous system metastasis; 4) Severe gastrointestinal dysfunction (bleeding, severe inflammation, obstruction, or diarrhea greater than grade 2); 5) Serious infections (CTC AE\\> Grade 2) occurred within 4 weeks prior to enrollment, such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc., and symptoms and signs of infection within 2 weeks prior to enrollment requiring intravenous antibiotic treatment (except for prophylactic antibiotic use); 6) Occurrence of arterial\u002Fvenous thrombosis events, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within 1 year before enrollment; 7) Have clinical symptoms or heart diseases that are not well controlled, such as: (1)NYHA2 or above heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction occurred within 1 year; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.\n\n8\\) Malignancies other than pancreatic cancer prior to initial use of the investigational drug, except malignancies with a low risk of metastasis and risk of death (5-year survival \\>90%), such as adequately treated cervical carcinoma in situ, skin basal cell or squamous cell carcinoma; 9) Co-active hepatitis B (HBV DNA≥2000IU\u002FmL or 104 copies\u002FmL), hepatitis C (hepatitis C antibody positive); 10) People with acquired immune deficiency syndrome (AIDS) or HIV positive, active syphilis infection; 11) A clear history of neurological or psychiatric disorders, including epilepsy or dementia: 12) Those planning to become pregnant, pregnant and lactating women; 13) In the investigator\\'s judgment, the subject has other factors that may lead to the forced termination of the study, such as non-compliance with the protocol, other serious medical conditions (including mental illness) requiring combined treatment, serious abnormalities in laboratory test values, family or social factors that may affect the safety of the subject or the collection of trial data.",{"count":228,"type":21},[64],"Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumor metastasis. The primary treatment regimen for advanced pancreatic cancer remains chemotherapy, which results in a median survival time of only 8 to 12 months. Therefore, there is an urgent need to explore new combination therapies to extend survival. Therefore, this study aims to evaluate the efficacy and safety of Adebrelimab and Chidamide in Combination with Gemcitabine and S1 as first-line treatment for locally advanced or metastatic pancreatic cancer.",[27],[347,348,349,350,351,352],"Adebrelimab","Chidamide","Gemcitabine","S1","First-Line","Locally Advanced or Metastatic Pancreatic Cancer","2025-12-01",{"date":355,"type":43},"2025-12-08",{"date":357,"type":43},"2024-09-10",{"date":359,"type":21},"2027-05-10",{"name":361,"class":50},"Liu Xiufeng",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":370,"targetDuration":4,"studyType":62,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":388},"100614273","phase-2-nimotuzumab-combined-with-nab-paclitaxelgemcitabine-in-the-perioperative-treatment-of-high-risk-resectableborderline-resectable-pancreatic-cancer-100614273","NCT07277452","Nimotuzumab Combined With Nab-paclitaxel\u002FGemcitabine in the Perioperative Treatment of High-risk Resectable\u002FBorderline Resectable Pancreatic Cancer","Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Nab-paclitaxel\u002FGemcitabine in the Perioperative Treatment of High-risk Resectable\u002FBorderline Resectable Pancreatic Cancer","NOTABLE-309","Inclusion Criteria:\n\n* 1\\. Age 18-75 years old, gender unlimited;\n* 2\\. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);\n* 3\\. Confirmed as resectable\u002Fborderline resectable pancreatic cancer by CT\u002FMRI imaging (resectability assessment refers to NCCN guidelines). For resectable pancreatic cancer, at least one of the following high-risk factors must be met: 1) CA199 \\> 500 U\u002Fml; 2) the maximum diameter of the primary tumor \\> 3.0 cm; 3) Severe weight loss (BMI \\\u003C 18.5 kg\u002Fm² OR involuntary weight loss \\> 15% within 6 months); 4) Severe pain (Numeric Rating Scale \\[NRS\\]≥ 4); 5) Definite regional lymph node metastasis (N1 or N2) OR suspicious regional lymph node metastasis (short-axis diameter of lymph nodes ≥15 mm);\n* 4\\. Voluntarily agree to sample collection (for KRAS gene testing and post-hoc analysis);\n* 5\\. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g\u002FdL; absolute neutrophil count (ANC)≥1.5×10\\^9\u002FL; platelets≥80×10\\^9\u002FL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \\> 60 mL\u002Fmin;\n* 6\\. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2;\n* 7\\. Life expectancy of at least 3 months;\n* 8\\. Women of childbearing age should have a negative result of serum HCG or urine pregnancy tests within 72 hours prior to randomization (Postmenopausal women who have had amenorrhea for at least 12 months are considered sterile and women known to have had tubal ligation are not required to undergo pregnancy tests) ;\n* 9\\. Good compliance and signed informed consent.\n\nExclusion Criteria:\n\n* 1\\. Previous treatment for pancreatic cancer.\n* 2\\. Accompanied by other serious diseases, including but not limited to: active infections; unmanageable diabetes mellitus and uncontrolled hypertension (SBP\\>160mmHg or DBP\\>100mmHg); compensatory heart failure (NYHA grade III and IV), unstable angina or poorly controlled arrhythmias within 3 months prior to randomization; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; digestive tract obstruction; respiratory insufficiency and severe lung disease; central nervous system disease or mental illness;\n* 3\\. Clinically diagnosed as local recurrence of pancreatic cancer, or there is evidence of peritoneal\u002Fother distant metastases;\n* 4.History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* 5\\. Presence of bleeding or coagulation disorders;\n* 6\\. Known allergy to prescription or any component of the prescription used in this study;\n* 7\\. Known HIV infection, syphilis infection, or active hepatitis (hepatitis B or C);\n* 8\\. Women who are pregnant or are breastfeeding;\n* 9.Other reasons that are not suitable to participate in this study according to the researcher's judgment.",{"count":371,"type":21},156,[64],"This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \\& Institute (as leading centers), its main purpose is to evaluate the clinical efficacy and safety of Nimotuzumab combined with nab-paclitaxel plus gemcitabine (AG) in the perioperative treatment of high-risk resectable\u002Fborderline resectable pancreatic cancer.",[27],[376,377,378],"Nimotuzumab","resectable pancreatic cancer","borderline resectable pancreatic cancer","2025-11-30",{"date":381,"type":43},"2025-12-11",{"date":383,"type":21},"2025-12-10",{"date":385,"type":21},"2029-12-10",{"name":387,"class":50},"The First Affiliated Hospital with Nanjing Medical University",2,{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":62,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":82},"100581569","effects-of-peptamen-16-in-malnourished-patients-or-at-risk-with-pancreatic-neoplasia-undergoing-cephalic-pancreaticoduodenectomy-cpd-a-mechanistic-study-100581569","NCT06852014","Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study","Effects of Peptamen 1.6 in Malnourished Patients (or in Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Study Mechanistic.","Inclusion Criteria:\n\n* Ambulatory patients who are malnourished or at risk of malnutrition, with a confirmed diagnosis of neoplasms of the periampullary region, pancreas, and duodenum, or pancreatic cancer, and who have undergone cephalic pancreaticoduodenectomy (CPD).\n* No prior neoadjuvant treatment (preoperative chemotherapy or radiotherapy): Patients must not have received neoadjuvant therapy as these treatments can affect metabolism, nutritional status, and gut microbiota, potentially interfering with the objectives of the study's nutritional intervention.\n\nExclusion Criteria:\n\n* Refusal to sign informed consent: Informed consent is a mandatory requirement for study participation. Any patient unwilling to participate voluntarily will be excluded.\n* Patients who underwent surgery more than three months ago will be excluded, as the nutritional intervention must begin in the immediate postoperative period to adequately evaluate its impact on nutritional and metabolic status.\n* Presence of severe cardiac disease, nephropathy, or other severe comorbidities: Conditions such as severe cardiac disease, renal failure, or comorbidities that could induce malnutrition or impair the patient's ability to tolerate nutritional treatment will be exclusion criteria. These conditions may interfere with assessing the effects of nutritional supplementation in the context of pancreatic cancer treatment.\n* Diarrhoea associated with antibiotics, laxatives, or osmotically active agents: Diarrhoea caused by medications may alter nutrient absorption and affect tolerance to the nutritional supplement, potentially skewing results attributable solely to the nutritional intervention.\n* Treatment with other nutritional support: Patients receiving other oral nutritional supplement, enteral or parenteral nutrition will be excluded, as interactions with the studied formula could confound the efficacy results of the study's nutritional intervention.\n* Pregnancy or possibility of becoming pregnant.\n* Type 1 or Type 2 diabetes with HbA1c \\>8%.\n* Galactosaemia, fructosaemia, or allergies to components of the nutritional supplement.",{"count":147,"type":21},[94],"Malnutrition is a common challenge in patients with pancreatic cancer undergoing cephalic pancreaticoduodenectomy (CPD), impacting postoperative recovery and overall prognosis. Nutritional support plays a crucial role in optimising metabolic, inflammatory, and digestive outcomes. This randomised, double-blind, crossover clinical trial aims to evaluate the effects of Peptamen 1.6, a hydrolysed whey protein-based enteral formula, compared to Resource HP\u002FHC, a high-protein and high-calorie polymeric formula, in malnourished or at-risk patients with pancreatic cancer undergoing PD.\n\nThe study comprises both in vivo and in vitro analyses. The in vivo component will assess the impact of Peptamen 1.6 on digestive tolerance, amino acid absorption, nutritional status, metabolic profile, inflammatory markers, and gut microbiota composition. The in vitro component will utilise human intestinal organoid models to explore how enteral nutrition formulations influence intestinal permeability and metabolism, with a focus on microbiota interactions.\n\nPrimary outcomes include improvements in metabolic status, assessed through serum biomarkers (albumin, immune markers, intestinal permeability, and myosin profile), inflammatory status via peripheral blood mononuclear cells (PBMCs), and microbiota shifts in faecal samples. Additionally, adherence to treatment, digestive tolerance, and changes in body composition will be monitored using bioelectrical impedance, dynamometry, and functional mobility tests.\n\nBy elucidating the mechanisms through which different enteral nutrition strategies influence clinical, physiological, and molecular parameters, this study aims to enhance personalised nutritional interventions for patients with pancreatic cancer. The findings could contribute to optimising nutritional support strategies, ultimately improving patient outcomes following CPD.",[27,400],"Cephalic Duodenopancreatectomy",[155,402,403,404,405,406],"malnutrition","pancreaticoduodenectomy","oral nutritional supplement","gut microbiota","organoids","2025-08-26",{"date":409,"type":43},"2025-09-02",{"date":411,"type":43},"2025-05-29",{"date":105,"type":21},{"name":414,"class":50},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":257,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":424,"studyType":23,"phases":4,"briefSummary":425,"conditions":426,"keywords":443,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":297},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",{"count":423,"type":21},600,"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[427,428,429,430,431,432,27,433,434,435,436,437,438,439,440,441,442],"Cancer Diagnosis","Liver Cancer, Adult","Cancer Screening","Colorectal Cancer (CRC)","Gastric Cancers","Normal Physiology","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Precancerous Conditions","Pancreatitis","Adenoma Colon Polyp","Gastric Ulcer","Oesophagitis","Cirrhoses, Liver",[444,445,429,433,267,310,446,435,447,448,438,449,450,441,451],"Pan-cancer","Deep Learning Models","Gastric Cancer","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":454,"type":43},"2025-04-24",{"date":456,"type":43},"2022-09-01",{"date":458,"type":21},"2025-07-28",{"name":460,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":202,"enrollmentInfo":468,"targetDuration":4,"studyType":62,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":4},"100588215","phase-2-ag-plus-nimotuzumab-sequential-irreversible-electroporation-ablation-for-locally-advanced-pancreatic-cancer-100588215","NCT06938503","AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","A Prospective, Single-Arm Study of Nab-paclitaxel\u002FGemcitabine Combined With Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* 1\\. Age 18-75 years old, gender unlimited;\n* 2\\. Histologically or cytologically confirmed pancreatic cancer;\n* 3\\. Confirmed as locally advanced pancreatic cancer by CT\u002FMRI imaging, with no evidence of distant metastasis;\n* 4\\. No prior chemotherapy or other tumor systemic therapy;\n* 5\\. Measurable disease according to RECIST criteria v1.1;\n* 6\\. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g\u002FdL; absolute neutrophil count (ANC)≥1.5×10\\^9\u002FL; platelets≥100×10\\^9\u002FL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \\> 60 mL\u002Fmin;\n* 7\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;\n* 8\\. Life expectancy is expected to be ≥3 months;\n* 9\\. Fertile subjects are willing to take contraceptive measures during the study period.\n* 10\\. Good compliance and signed informed consent voluntarily.\n\nExclusion Criteria:\n\n* 1\\. Refuse chemotherapy or surgery;\n* 2\\. Other part (e.g. peritoneum, lung, bone, brain) metastasis;\n* 3\\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* 4\\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\\>160mmHg or DBP\\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;\n* 5\\. Undergone major surgery within 30 days;\n* 6\\. Participated in other drug related clinical trials within 4 weeks;\n* 7\\. Known allergy to prescription or any component of the prescription used in this study;\n* 8\\. With HIV, or active hepatitis (hepatitis B, hepatitis C);\n* 9\\. Failure to recover from treatment-related toxicity to ≤ grade 1 (adverse events such as alopecia judged by the researcher not to affect the treatment with the research drug are excluded);\n* 10.Other reasons that are not suitable to participate in this study according to the researcher's judgment.",{"count":469,"type":21},48,[64],"This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel\u002Fgemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).",[27],"2025-04-14",{"date":475,"type":43},"2025-04-22",{"date":477,"type":21},"2025-04-21",{"date":479,"type":21},"2028-04-28",{"name":218,"class":50},{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":62,"phases":490,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":82},"100577605","gut-microbiota-analysis-in-patients-undergoing-duodencephalopancreasectomy-for-pancreatic-cancer-100577605","NCT06800469","Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer","Gut Microbiota Analysis in Patients Undergoing Duodencephalopancreasectomy for Pancreatic Cancer (MIcRobiome Analysis in Patients UnderGoing PancrEatico-duodenectomy for Pancreatic Cancer MIRAGE Study)","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of resectable pancreatic adenocarcinoma with indication for \"upfront\" surgical treatment\n* ASA (American Society of Anesthesiology) score \\\u003C 4\n* Obtaining informed consent\n\nExclusion Criteria:\n\n\\- Pregnant or lactating women",{"count":489,"type":21},30,[94],"Pancreatic head cancer represents one of the most frequent malignancies with an incidence of about 13500 new cases each year. The primary objective of the study is to test whether there are bacterial species associated with increased risk of complications in patients with peri-ampullary neoplasia undergoing DCP.",[27],[30],"2025-01-28",{"date":496,"type":43},"2025-01-30",{"date":498,"type":43},"2022-07-11",{"date":500,"type":21},"2025-07-01",{"name":502,"class":50},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":257,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":512,"conditions":513,"keywords":516,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100574550","prevenpanc-project-a-spanish-multicenter-study-for-pancreatic-cancer-prevention-100574550","NCT06760741","PREVENPANC Project: a Spanish Multicenter Study for Pancreatic Cancer Prevention","PREVENPANC","Inclusion Criteria:\n\n* Patients with a recent diagnosis of pancreatic cancer in the general population.\n* High-risk individuals under follow-up in high-risk clinics (hereditary syndromes, familial pancreatic cancer).\n\nExclusion Criteria:\n\n* Patients under 18 years old.\n* Patients who have undergone treatment for pancreatic cancer.",{"count":511,"type":21},900,"Background: Pancreatic cancer (PC) is an aggressive cancer with only a 7% 5-year survival rate, primarily due to late-stage diagnosis. In Spain, its incidence is rising, and by 2030, it is expected to become the second leading cause of cancer-related death worldwide. Approximately 3% of PCs occur in the context of hereditary pancreatic cancer (HPC) predisposition syndromes. Studies have shown that up to 40% of genetic mutations associated with PC in individuals under 60 years old would not have been identified using traditional clinical criteria for genetic testing. Presymptomatic genetic testing is recommended for relatives of patients with hereditary syndromes to identify those at higher risk of PC and to include them in screening programs to alter the natural history of the disease. However, there is no robust evidence supporting the best tool for early diagnosis in at-risk individuals. Currently, screening relies on endoscopic ultrasound or magnetic resonance imaging, which yield suboptimal results.\n\nAims: By studying the clinical, molecular, and genetic characteristics of PC patients and their families, this project aims to identify factors conferring higher PC risk and to adopt preventive measures while evaluating the efficacy of current screening strategies. Additionally, the project includes a traslational subproject to identify new hereditary genes associated with increased PC risk and novel molecules (biomarkers, specifically miRNAs) with diagnostic potential. These biomarkers could serve as non-invasive tools to identify individuals at increased risk of PC through blood tests, enabling preventive measures or early diagnosis.\n\nGiven the low incidence of PC (albeit with high mortality), collaborative studies are essential to achieve meaningful results. The current project represents the first Spanish multicenter population-based registry for PC, integrating clinical data and biological sample collection alongside a control group. Its goal is to prevent PC and foster collaboration between basic research and clinical application in Spain within a proven collaborative framework.\n\nEstablishing the best strategy to detect high-risk individuals for PC within the general population.\n\nIdentifying new PC risk genes to expand the identification of at-risk individuals.\n\nDetermining effective prevention strategies for high-risk individuals. Creating a national network, \"PREVENPANC,\" for collaborative PC research, including the collection of biological samples (blood) from all enrolled patients.",[27,514,515],"Hereditary Pancreatic Cancer","Familial Pancreatic Cancer",[323,155,517,518,519,520],"High risk pancreatic cancer","Hereditary pancreatic cancer","Familial pancreatic cancer","miRNA pancreatic cancer","2025-01-03",{"date":523,"type":43},"2025-01-07",{"date":525,"type":21},"2025-01",{"date":527,"type":21},"2026-12",{"name":529,"class":50},"Hospital Clinic of Barcelona",{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":538,"conditions":539,"keywords":543,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":82},"100573530","neutrophil-to-lymphocyte-ratio-and-ca-199-as-predictors-of-perineural-invasion-in-pancreatic-cancer-100573530","NCT06747481","Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer","Inclusion Criteria:\n\n* Patient with a histopathological diagnosis of adenocarcinoma.\n* Surgical resection of the neoplasm.\n* Preoperative blood count allowing calculation of the neutrophil-to-lymphocyte ratio and preoperative CA 19.9, both before and after neoadjuvant therapy.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of another histological type.\n* Patients with incomplete data.\n* Patients who were not operated on.",{"count":537,"type":21},323,"Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain. This disease is associated with a poor prognosis, reflected by a 5-year survival rate of less than 5% when all stages are grouped together.\n\nSeveral prognostic factors for pancreatic cancer have been identified. The most relevant include preoperative levels of carbohydrate antigen 19-9 (CA 19.9), surgical margins after resection, venous and\u002For arterial vascular involvement, and histopathological features such as affected locoregional lymph nodes, or perineural and lymphovascular invasion. Among all these factors, perineural invasion may be the primary independent factor affecting prognosis, particularly in patients with relatively favorable pathological features.\n\nThe identification of perineural invasion before surgery could influence the clinical management of these patients. It may facilitate risk stratification, allowing the identification of patients who would benefit most from neoadjuvant treatments or more aggressive surgical procedures, such as vascular resections. However, perineural involvement is very difficult to detect preoperatively.\n\nOnly a few studies have analyzed the possible relationship between CA 19.9 and perineural invasion, and their results are inconsistent. Alternatively, some studies have demonstrated the utility of preoperative multidetector computed tomography in detecting extrapancreatic perineural invasion. However, these radiological tests are still not useful for directly detecting microscopic perineural invasion, especially in early stages.\n\nOn the other hand, in recent years, evidence has supported that the systemic inflammatory response may play an important role in the prognosis of different malignancies. Among these inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) has gained prominence. Regarding pancreatic cancer, many studies suggest that elevated preoperative NLR levels are associated with a worse prognosis. However, no studies have yet been published analyzing a possible relationship between this inflammatory marker and perineural invasion.\n\nThe main objective of this study is to correlate the neutrophil-to-lymphocyte ratio (NLR) and CA 19.9 with histopathologically confirmed perineural invasion and, in this way, investigate these data as potential preoperative markers of perineural invasion in pancreatic cancer. Our working hypothesis is that preoperative NLR and CA 19.9 are potential markers of perineural invasion.\n\nAs secondary objectives, we aim to study the effect of neoadjuvant therapy on inflammatory markers (NLR) and tumor markers (CEA and CA 19.9) in pancreatic cancer.",[27,540,541,542],"Perineural Invasion","Neutrophil-to-Lymphocyte Ratio","CA 19.9",[30,544,541,542],"perineural invasion","2024-12-20",{"date":547,"type":43},"2024-12-24",{"date":549,"type":43},"2020-01-01",{"date":551,"type":21},"2025-09-30",{"name":553,"class":50},"University of Las Palmas de Gran Canaria"]